Phenotypes Associated with This Genotype

Genotype
MGI:5316848

• Allelic Composition: Cav1^tm1Mls/Cav1^tm1Mls
• Genetic Background: FVB.Cg-Cav1^tm1Mls

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

abnormal homeostasis ( J:182288 )

• increase in lactate levels following 3-mercaptopicolinic acid treatment

• elevated circulating peroxide levels and a small decrease in circulating pyruvate levels

decreased susceptibility to diet-induced obesity ( J:182288 )

• when placed on a high fat diet

abnormal circulating amino acid level ( J:182288 )

• elevated circulating branched-chain amino acid levels

increased blood urea nitrogen level ( J:182288 )

increased circulating glycerol level ( J:182288 )

• following 3-mercaptopicolinic acid treatment

increased oxygen consumption ( J:182288 )

abnormal respiratory quotient ( J:182288 )

• variability in the respiratory exchange ratio over a 24 hour period is reduced

increased respiratory quotient ( J:182288 )

abnormal glucose homeostasis ( J:182288 )

• maintain glucose levels better in the fasted state better than wild-type controls

• exposure to 3-mercaptopicolinic acid causes a larger drop in glucose levels compared to wild-type mice

hyperglycemia ( J:182288 )

• upon refeeding display fairly severe hyperglycemia

increased circulating insulin level ( J:182288 )

enhanced gluconeogenesis ( J:182288 )

• enhanced hepatic gluconeogenesis

• treatment with enoximone, a phospodiesterase inhibitor, potently increases glucose levels

• following a glycerol bolus, glycerol induced glucose production is enhanced but glycerol clearance is delayed

decreased liver glycogen level ( J:182288 )

• in the fed state

increased liver glycogen level ( J:182288 )

• in moderately fasted mice

insulin resistance ( J:182288 )

decreased circulating adiponectin level ( J:182288 )

• reduced total circulating levels and a decrease in the proportion of the HMW form

abnormal free fatty acids level ( J:182288 )

• delay in suppression of free fatty acid levels following refeeding

• impaired beta3-AR agonist induced release of free fatty acids

increased triglyceride level ( J:182288 )

• in fed and fasted mice

enhanced lipolysis ( J:182288 )

cellular

abnormal cellular respiration ( J:182288 )

• MEFs display a preference for glycolysis in glucose-deprived media

abnormal respiratory electron transport chain ( J:182288 )

• expression analysis indicates altered mitochondrial function

• mitochondria in MEFs display dramatically increased membrane potential

• however, mitochondria isolated from liver and lung tissue display similar function compared to wild-type controls

adipose tissue

decreased total body fat amount ( J:182288 )

• reduced fat mass

abnormal adipose tissue physiology ( J:182288 )

• enhanced uptake of leucine in mildly fasted mice

growth/size/body

weight loss ( J:182288 )

• lose more weight when fasted

decreased susceptibility to diet-induced obesity ( J:182288 )

• when placed on a high fat diet

increased liver weight ( J:182288 )

• under all conditions tested

behavior/neurological

increased food intake ( J:182288 )

muscle

abnormal skeletal muscle morphology ( J:182288 )

• skeletal muscle tissue has a darker appearance indicating an increased mitochondrial content

liver/biliary system

increased liver weight ( J:182288 )

• under all conditions tested

decreased liver glycogen level ( J:182288 )

• in the fed state

increased liver glycogen level ( J:182288 )

• in moderately fasted mice

decreased susceptibility to diet-induced hepatic steatosis ( J:182288 )

• fasting induced and high fat diet induced hepatic steatosis are reduced

abnormal liver physiology ( J:182288 )

• alternate day fasting has no effect of hepatic lipid content unlike in wild-type mice

• hepatic triglyceride synthesis appears to be reduced